Advertisement

Topics

CHMP recommends bevacizumab biosimilar for European approval

10:10 EST 13 Nov 2017 | ecancermedicalscience

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to bevacizumab. ABP 215 has been recommended for approval for the...

Original Article: CHMP recommends bevacizumab biosimilar for European approval

NEXT ARTICLE

More From BioPortfolio on "CHMP recommends bevacizumab biosimilar for European approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...